Timed sequential chemotherapy with concomitant Granulocyte Colony-Stimulating Factor for high-risk acute myelogenous leukemia: a single arm clinical trial

@article{He2002TimedSC,
  title={Timed sequential chemotherapy with concomitant Granulocyte Colony-Stimulating Factor for high-risk acute myelogenous leukemia: a single arm clinical trial},
  author={Xing-Yue He and Paul J. Elson and Brad L. Pohlman and Alan Eli Lichtin and Mohamad A. Hussein and Steve Andresen and Matt E. Kalaycio},
  journal={BMC Cancer},
  year={2002},
  volume={2},
  pages={12 - 12}
}
BackgroundThe timed-sequential chemotherapy regimen consisting of etoposide, mitoxantrone and cytarabine (EMA) is an effective therapy for relapsed or refractory acute myelogenous leukemia (AML). We postulated that granulocyte colony-stimulating factor (G-CSF) might enhance the cytotoxicity of EMA by increasing the proportion of leukemic blasts in S-phase. We added G-CSF to EMA (EMA-G) for therapy of advanced high-risk AML patients.MethodsHigh-risk AML was defined as refractory, relapsed or… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 49 REFERENCES

A phase III study of daunorubicin vs idarubicin vs mitoxantrone for older adult patients (>55 yrs) with acute myelogenous leukemia (AML): a study of the Eastern Cooperative Oncology Group (E3993)

JM Rowe, D Neuberg, W Friedenberg
  • Blood 1998,
  • 1998
VIEW 1 EXCERPT

Inpatient management of acute leukemia.

  • Cleveland Clinic journal of medicine
  • 1997
VIEW 1 EXCERPT